These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37995759)

  • 1. Intralesional or intraorbital rituximab injection for the management of biopsy-proven idiopathic orbital inflammation involving the lacrimal gland.
    Demirci H; Ciftci S; Teo HMT; Demirci FY; Shinder R; Elner VM
    Can J Ophthalmol; 2024 Oct; 59(5):e496-e500. PubMed ID: 37995759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma.
    Demirci H; Kauh CY; Rajaii F; Elner VM
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S70-S71. PubMed ID: 26950471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports.
    Savino G; Battendieri R; Siniscalco A; Mandarà E; Mulè A; Petrone G; Traina S; Riso M
    Rheumatol Int; 2015 Jan; 35(1):183-8. PubMed ID: 24879326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional corticosteroid injections as treatment for non-infectious orbital inflammation.
    Reggie S; Neimkin M; Holds J
    Orbit; 2018 Feb; 37(1):41-47. PubMed ID: 28872378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraorbital injection of triamcinolone acetonide in patients with idiopathic orbital inflammation.
    Leibovitch I; Prabhakaran VC; Davis G; Selva D
    Arch Ophthalmol; 2007 Dec; 125(12):1647-51. PubMed ID: 18071116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The preliminary observation of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma].
    Yang JP; Pang X; Zhang K; Wang LL; Zhu Y
    Zhonghua Yan Ke Za Zhi; 2020 Nov; 56(11):839-845. PubMed ID: 33152842
    [No Abstract]   [Full Text] [Related]  

  • 7. CyberKnife radiosurgery and rituximab in the successful management of sclerosing idiopathic orbital inflammatory disease.
    On AV; Hirschbein MJ; Williams HJ; Karesh JW
    Ophthalmic Plast Reconstr Surg; 2006; 22(5):395-7. PubMed ID: 16985430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Idiopathic orbital inflammatory syndrome: Report of 24 cases].
    Khochtali S; Zayani M; Ksiaa I; Ben Meriem I; Zaouali S; Jelliti B; Khairallah M
    J Fr Ophtalmol; 2018 Apr; 41(4):333-342. PubMed ID: 29685738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study.
    Savino G; Battendieri R; Balia L; Colucci D; Larocca LM; Laurenti L; De Padua L; Blasi MA; Balestrazzi E
    Cancer Sci; 2011 Aug; 102(8):1565-7. PubMed ID: 21564418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsing migratory idiopathic orbital inflammation: six new cases and review of the literature.
    Avni-Zauberman N; Tripathy D; Rosen N; Ben Simon GJ
    Br J Ophthalmol; 2012 Feb; 96(2):276-80. PubMed ID: 21527417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete resolution of idiopathic sclerosing orbital inflammation after treatment with rituximab.
    Abell RG; Patrick A; Rooney KG; McKelvie PA; McNab AA
    Ocul Immunol Inflamm; 2015 Apr; 23(2):176-9. PubMed ID: 24354478
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections.
    Savino G; Battendieri R; Gari M; Caputo CG; Laurenti L; Blasi MA
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1251-5. PubMed ID: 23625184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Epidemiological, Clinical, and Histopathological Characteristics of Lacrimal Gland Biopsies in a Tertiary Care Center in Israel.
    Priel A; Vishnevskia-Dai V; Hochma L; Gildener-Leapman J; Ben Simon GJ; Rosner M; Antman G; Zloto O
    Isr Med Assoc J; 2018 Feb; 20(2):104-108. PubMed ID: 29431305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.
    Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
    JAMA Ophthalmol; 2014 May; 132(5):572-8. PubMed ID: 24652467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial.
    Iraji F; Danesh F; Faghihi G; Siadat A; Mokhtari F; Talakoob M; Hafezi H
    Int Immunopharmacol; 2019 Aug; 73():94-97. PubMed ID: 31082727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic features and outcomes of bilateral lacrimal gland lesions.
    He L; He W
    PLoS One; 2024; 19(7):e0305717. PubMed ID: 38959275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric Idiopathic Orbital Inflammation: Clinical Features of 30 Cases.
    Spindle J; Tang SX; Davies B; Wladis EJ; Piozzi E; Pellegrini M; Lally SE; Shields C; Shinder R
    Ophthalmic Plast Reconstr Surg; 2016; 32(4):270-4. PubMed ID: 27337659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow up of systemic rituximab therapy as first-line and salvage therapy for idiopathic orbital inflammation and review of the literature.
    Abou-Hanna JJ; Tiu Teo HM; Thangavel R; Elner VM; Demirci H
    Orbit; 2022 Jun; 41(3):297-304. PubMed ID: 33478316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
    Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
    Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.